What bothered me most was the increase in staff costs from $500,000 the previous quarter to now $700,000. I have emailed the investor relations person with a few questions - that is, is it extra sales staff. If anything useful comes back, I will post.
Before Osteopore products can be sold on the Chinese mainland, they have to pass trials, so probably a couple of years.
Ann: Activities Update Qtr Ending March 2023 and Appendix 4C, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $2.081M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $2.977K | 231.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 798952 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 557010 | 3 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSX (ASX) Chart |